InnoCore’s proprietary technology, SynBiosys® is best-in-class and is the only current solution for formulating complex biologic molecules and peptides as a stable, tunable and scalable sustained release LAI dosage forms.
SynBiosys® maintains essential biological activity of the formulated APIs and brings other additional value-added benefits.
In partnership with leading global pharma companies, InnoCore currently has over 10 active programs running for developing novel peptide and biologic LAI formulations based on its proprietary SynBiosys® platform.
Whether you are a Large Pharma, Biotech, Generic or Animal Health company, InnoCore’s bespoke offering will support you in developing unique long-acting dosage forms of your API.
Different structures of license and development agreements are available, depending on your needs and preferences.
We create bespoke teams with a mixture of expertise depending on the project, that works for you, not only during the first feasibility phase, but also during all subsequent product development phases.
"*" indicates required fields